GAIA

What GAIA does

GAIA AG is a Hamburg, Germany-based digital therapeutics company founded in 1997 that develops evidence-based, CE-marked and FDA-cleared digital medical devices across mental health, neurology, chronic disease and cardiovascular indications. Its products are delivered through the proprietary broca platform, which provides personalized, web-based branching dialogue content that adapts to individual patient responses using AI/ML-driven personalization and adaptive algorithms; underlying interventions are grounded in cognitive behavioral therapy, schema therapy, mindfulness, and related psychological frameworks validated through 19+ randomized controlled trials and 2 meta-analyses. The portfolio spans 20+ commercially active products and 70+ developed products, with flagship assets including deprexis (depression, 13 RCTs), velibra (anxiety), attexis (adult ADHD), vorvida (alcohol reduction), somnovia (insomnia), priovi (borderline personality disorder), elevida (MS fatigue), levidex (MS), and newer entries such as lipodia (hypercholesterolemia), mylovia (female sexual dysfunction), and covivio (type 2 diabetes).

GAIA monetizes through three primary streams: (1) DiGA reimbursement under Germany's Digital Healthcare Act (DVG), where physicians prescribe listed digital therapeutics that are reimbursed by statutory health insurance (GKV) with no patient co-payment; (2) pharmaceutical licensing and co-promotion agreements — including exclusive partnerships with Daiichi Sankyo Europe (lipodia), co-promotion with Servier/MEDICE Health Family (deprexis, attexis), and strategic partnerships with Chugai Pharma Germany — generating upfront, milestone, and royalty income; and (3) direct enterprise contracts with health insurers such as HanseMerkur, Sanitas, DAK Gesundheit, and AOK for population health offerings. Distribution operates through the BfArM DiGA directory, physician prescription channels, traditional pharmacy dispensing, and pharma sales forces. The company operates from Hamburg and through a US subsidiary (GAIA America Inc, New York), serving markets across Europe, North America, the Middle East, South America, and Asia, with 251–500 employees and a multidisciplinary team spanning physicians, clinical scientists, regulatory specialists, and software engineers.

Name

GAIA

Legal name

GAIA AG

Website

https://gaia-group.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

251–500 employees

Short description

GAIA AG is a Hamburg-based digital therapeutics company founded in 1997 that develops CE-marked, FDA-cleared, evidence-based software medical devices for mental health, neurology, and chronic disease, delivered through its proprietary broca platform and reimbursed primarily via Germany's DiGA framework and pharmaceutical licensing partnerships.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Condition-specific Digital Therapeutics (DTx) (HLACANAA), Behavioral Health Digital Therapeutics (DTx) & Virtual Care Partner Management (HLAEAHAJ)

Keywords

• Digital therapeutics software
• Prescription health applications
• DiGA mental health products
• Evidence-based clinical software
• Behavioral health interventions

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital Health Application (DiGA) Reimbursement: Products prescribed in Germany are covered by statutory health insurance (GKV) without patient co-payment. Revenue generated through the DiGA prescription pathway and health insurance reimbursement framework established by the German Digital Healthcare Act (DVG).
2. Pharmaceutical Licensing and Co-Development: Licensing agreements with pharmaceutical companies for branded digital therapeutics, including upfront payments, milestone achievements, and ongoing royalties. Partnerships with companies like MEDICE Health Family, Daiichi Sankyo, and Servier for product distribution and market access.
3. Health Insurance Enterprise Partnerships: Direct partnerships with health insurers such as HanseMerkur, Sanitas (Switzerland), and DAK Gesundheit for digital health offerings and population health management programs.

Pricing tiers

Distribution channels4 records

Marketing channels6 records

Core offering

GAIA develops and commercializes evidence-based, prescription-grade digital therapeutics (DTx) for mental health and chronic disease management, delivered through its proprietary broca® web-based platform. Products are clinically validated via randomized controlled trials (RCTs), hold CE marking and FDA clearance as medical devices, and are predominantly reimbursed through the German DiGA statutory health insurance framework. The portfolio spans 70+ products covering depression, anxiety, ADHD, insomnia, borderline personality disorder, multiple sclerosis, cancer support, and cardiovascular conditions, sold via physician prescription, pharmaceutical licensing, and enterprise health-insurer contracts.

Product overview

GAIA operates as a platform-plus-products company offering a portfolio of 20+ clinically validated digital therapeutics (DTx) delivered through the proprietary broca® technology platform. The platform provides personalized, branching dialogue-based content delivery that adapts to individual user responses. Products span multiple therapeutic areas including mental health (deprexis for depression, velibra for anxiety, attexis for ADHD, reviga for burnout, vorvida for alcohol reduction, priovi for borderline personality disorder), neurology (somnovia for insomnia, emyna for epilepsy), chronic disease management (elevida and levidex for MS, lancivis for cancer, reclarit for rheumatoid arthritis, klariva for psoriasis, covivio for diabetes, lipodia for hypercholesterolemia, vimida for post-COVID fatigue), and other conditions (ceprica for migraines, relevis for pain, optimune for breast cancer, mylovia for female sexual dysfunction, modia for opioid use disorder). The company pioneered digital therapeutics in Germany, with first product launched in 2001, and currently has 8 prescribable DiGA (digitale Gesundheitsanwendungen) products listed in Germany's DiGA directory, all with permanent reimbursement status.

Differentiator

Problem solved

Functional benefit

Brands

• broca: Proprietary technology platform for personalized, web-based digital therapeutics solutions.

Products and services

• deprexis Evidence-based digital therapeutic for depression delivering cognitive behavioral therapy and mood tracking through an online program; supported by 13+ RCTs and multiple meta-analyses. Targeted at adult patients with depression seeking evidence-based digital intervention, prescribed under the German DiGA framework and reimbursed via statutory health insurance.
• velibra Digital therapeutic for anxiety disorders including generalized anxiety disorder, social phobia, and panic disorder, based on cognitive behavioral therapy. For adults with anxiety disorders prescribed under the DiGA framework.
• attexis Digital intervention based on CBT and mindfulness principles for adults with ADHD, providing therapeutic methods and exercises to support well-being. Received permanent BfArM approval August 2025.
• somnovia Interactive digital CBT-I intervention for adults with non-organic insomnia, providing comprehensive solutions for restoring restful sleep.
• vorvida Digital therapeutic targeting harmful alcohol consumption through evidence-based psychological therapies; designed for adults trying to reduce excessive drinking.
• elevida Digital therapeutic specifically designed for multiple sclerosis-related fatigue, based on cognitive behavioral therapy and mindfulness principles.
• levidex Psychoneuroimmunological digital intervention for MS patients focused on enhancing quality of life and overall well-being, implemented as a DiGA.
• emyna Digital therapeutic for epilepsy patients, aiding in understanding of triggers and symptoms to facilitate informed management for enhanced well-being.
• priovi Digital therapeutic for borderline personality disorder based on schema therapy; positioned as a scalable, on-label treatment for BPD. Phase 3 RCT with 580 participants confirmed effectiveness.
• optimune Digital therapeutic empowering women with breast cancer through therapeutic techniques for active condition management, stress coping, and healthy lifestyle changes.
• lancivis Digital therapeutic providing evidence-based psychological therapies for cancer patients to manage emotional stress, improve quality of life, and reduce fatigue.
• reclarit Digital therapeutic supporting adult patients with rheumatoid arthritis in managing symptoms through therapeutic techniques and trusted information sources.
• reviga Digital therapeutic supporting individuals suffering from burnout and chronic stress, providing assistance in managing symptoms and implementing healthier lifestyles.
• liebria Internet-based digital intervention for patients with primary hypertension, assisting in condition management through evidence-based psychological and psychotherapeutic techniques.
• mylovia Self-guided digital intervention for female sexual dysfunction and sexual pain disorder based on CBT and mindfulness principles; efficacy demonstrated in a randomized controlled trial published in npj Digital Medicine in 2026.
• lipodia Next-generation digital therapeutic designed to support adults living with hypercholesterolemia. Commercialized in Europe through an exclusive partnership with Daiichi Sankyo Europe.
• covivio Digital therapeutic empowering individuals with type 2 diabetes through adoption of effective self-management strategies; currently in Phase 2 development.
• amiria Digital therapeutic enhancing well-being of Multiple Sclerosis patients with comorbid depression, proven effective in reducing depressive symptoms.
• ceprica Digital therapeutic offering tailored relief and support to patients suffering from migraines through effective cognitive behavioral therapy exercises.
• klariva Digital therapeutic elevating well-being of individuals with psoriasis by employing advanced evidence-based psychological methodologies.
• relevis Digital therapeutic delivering multimodal pain management interventions specifically designed for users experiencing subacute or chronic non-specific low back pain, knee pain, and hip pain.
• vimida Digital therapeutic offering evidence-based psychological therapies for post-viral chronic fatigue after COVID-19 infection, promoting recovery and well-being.
• modia Digital therapeutic delivering a comprehensive approach to support and facilitate recovery for individuals grappling with Opioid Use Disorder.
• plexus Digital behavior-change intervention designed to improve prescription behavior of physicians in ambulatory care settings, supporting more evidence-based prescription decisions.
• Rücken@Fit Digital therapeutic developed with AIRBUS for back pain management and stress, helping individuals stay in motion while enabling sustainable behavioral modification.

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• Daiichi Sankyo EuropecoreStrategic or Co-development Partner · 1 January 2024Strategic partnership with Daiichi Sankyo Europe for the lipodia digital therapeutic product, combining pharmaceutical and digital therapeutic approaches for patient treatment.
• ServiercoreChannel Partner/ Reseller/ Distributor · 1 January 2023Marketing partnership for Deprexis digital therapeutic for depression, with Servier handling distribution and promotion in specified markets.
• Chugai Pharma GermanycoreStrategic or Co-development Partner · 1 January 2023Partnership for rheumatoid arthritis digital therapeutic applications, combining Chugai's pharmaceutical expertise with GAIA's digital therapeutic platform.
• HanseMerkurmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Partnership for digital health offerings, providing HanseMerkur insured members access to GAIA's digital therapeutics through direct insurance coverage.
• SanitasmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Swiss health insurance partnership providing Sanitas policyholders access to GAIA's digital health solutions.
• DAK GesundheitmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Partnership for back-pain treatment digital therapeutics, providing DAK Gesundheit members access to prescribed digital health applications.
• AOKmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Health insurance coverage partnership providing AOK members access to GAIA's digital therapeutic products through statutory health insurance.
• OrexominorStrategic or Co-development Partner · 1 January 2023Former partnership for Deprexis in USA market, which was subsequently terminated.
• MEDICE Health FamilycoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Licensing agreement for Attexis digital therapeutic, granting MEDICE rights to commercialize the product.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Big Health: Big Health develops evidence-based digital therapeutics for mental health conditions including insomnia (Sleepio) and anxiety (Daylight), with a similar prescription/clinical-validation model. Both companies compete for the same payer, employer, and pharma-partner channels in mental health DTx.
• Akili Interactive: Akili Interactive develops FDA-cleared prescription digital therapeutics for ADHD and cognitive conditions (EndeavorRx, EndeavorOTC). Comparable to GAIA in regulatory-cleared DTx positioning, evidence generation via RCTs, and pursuit of prescription and OTC distribution pathways.
• Kaia Health: Kaia Health develops evidence-based digital therapeutics for chronic pain (back, knee, hip) and COPD, with a similar AI-personalized self-management model. Direct overlap with GAIA's relevis product for non-specific back/knee/hip pain and broader chronic-disease DTx positioning.
• Limbic: Limbic is a UK-based digital therapeutics company offering AI-supported CBT tools for anxiety and depression, available via the NHS. Comparable to GAIA in evidence-based mental health DTx with national payer integration.
• Oviva: Oviva is a European (Swiss-German) digital health company delivering app-based therapeutic programs for diabetes, obesity, and related chronic conditions, with statutory health insurance reimbursement in Germany/DiGA-adjacent frameworks. Comparable to GAIA in DACH-centric chronic-disease DTx and payer reimbursement model.
• HiDoc Technologies (Cara Care): Cara Care is a Germany-based digital therapeutics company focused on gastrointestinal conditions, listed in the German DiGA directory. Direct DiGA-market peer to GAIA with similar prescription pathway, statutory reimbursement, and patient-facing app delivery model.

Broad incumbents

• Hinge Health: Hinge Health is a large-scale digital musculoskeletal care platform combining wearable sensors, PT coaching, and digital interventions for back/joint pain. Comparable to GAIA's relevis product on musculoskeletal DTx but operates as a broad incumbent across the employer/payer ecosystem rather than narrow regulatory-cleared DTx.
• Lyra Health: Lyra Health is a leading employer-sponsored mental health benefits platform combining in-person therapy, coaching, and digital self-guided programs. Competes with GAIA for the same employer/payer mental-health budget but operates a broader blended-care model rather than regulatory-cleared DTx.
• Teladoc Health (Livongo): Teladoc Health (including the Livongo chronic-condition platform) is a global incumbent in virtual care and digital chronic disease management. Comparable to GAIA in chronic-disease digital interventions but operates at much broader scale across multiple care modalities and geographies.

Emerging players

• Welldoc: Welldoc develops FDA-cleared digital therapeutics for diabetes, hypertension, and cardiometabolic conditions, with health plan and pharma partnerships. Comparable to GAIA in regulatory-cleared DTx for chronic conditions and pharma co-promotion model, though at smaller scale and primarily US-focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/gaia_com
• LinkedInlinkedin.com/company/832643

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GAIA